NIH-funded research R01 grant

Fibroblasts in brain metastases help cancer grow and hide from treatment

Official title: Fibroblasts Support the Growth of Brain Metastasis by Rendering Cancer Cells Resistant to Chemotherapy and Inducing Immunosuppression in Tumor Microenvironment

Funded at Research Inst of Fox Chase Can Ctr · NIH-11345207 · Data updated 2026-11-12

In people with cancer that has spread to the brain, researchers are studying how lung cancer–driven fibroblasts in the brain help cancer cells grow, resist standard therapies, and dampen the immune response.

More Metastasis research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionResearch Inst of Fox Chase Can Ctr
NIH-funded
Lab location1 site (Philadelphia, United States)
Project startJune 1, 2023
Project endMay 31, 2028
Funding year2026
Award (this year)$412,500
NIH project number5R01CA276273-04
Project IDNIH-11345207 on NIH RePORTER

Who could benefit from this research

Could help

Adults with brain metastases from cancer (especially lung cancer) or those at risk of brain metastasis may be relevant for future clinical studies.

Less likely to help

The study is preclinical and may not immediately translate to benefits for all patients.

What this research studies

This project focuses on brain metastases from lung cancer and the role of metastasis-associated fibroblasts in the brain tumor microenvironment. It looks at a protein called placental growth factor (PGF) produced by these fibroblasts and how it may drive cancer cell growth and resistance to tyrosine kinase inhibitors, as well as suppress anti-tumor immunity. The study will test two aims: how MAF-derived PGF affects cancer cell proliferation and drug resistance, and how it causes immunosuppression in brain metastases. The researchers plan to use preclinical models and existing antibodies that can reach the brain to explore potential therapeutic strategies. Findings could point to new ways to overcome treatment resistance in brain metastases and improve outcomes for patients with metastatic lung cancer.

Why it matters

Potential benefit: If successful, the work could identify new targets to counter chemoresistance and immunosuppression in brain metastases, potentially guiding future therapies.

How similar studies have gone: Preclinical data suggest PGF-directed approaches may help in brain tumors, but translation to patients is still being explored.

Where this research is happening

  • Research Inst of Fox Chase Can Ctr
    Philadelphia, United States
    Active

Researchers

  • Principal investigator: Yang, Zeng-Jie — Research Inst of Fox Chase Can Ctr
  • Study coordinator: Yang, Zeng-Jie

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.